Modulation of cancer endocrine therapy by melatonin: a phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone

Biotransformation of melatonin in human breast cancer cell lines: role of sulfotransferase 1A1

“…As the sensitivity of estrogen‐dependent human breast cancer cell lines to tam was increased at physiological, nocturnal circulating melatonin levels (1 n m ) [43, 44], these interactions might not be relevant in patients. This is in line with data from a phase II study, in which melatonin was able to restore the sensitivity to tam in therapy‐resistant breast cancer patients [45].…”

Biotransformation of melatonin in human breast cancer cell lines: role of sulfotransferase 1A1

“…As the sensitivity of estrogen‐dependent human breast cancer cell lines to tam was increased at physiological, nocturnal circulating melatonin levels (1 n m ) [43, 44], these interactions might not be relevant in patients. This is in line with data from a phase II study, in which melatonin was able to restore the sensitivity to tam in therapy‐resistant breast cancer patients [45].…”

A Novel Melatonergic Signature Predicts Reccurence Risk and Therapeutic Response in Breast Cancer Patients

“…In a clinical trial, supplementing tamoxifen with melatonin has been found to prolong the pre-metastatic phase in patients with breast cancer [11]. In line with that finding, we found that patients with high ASMT expression levels tend to be more sensitive to treatment with tamoxifen and experience fewer relapses or longer phases before recurrence.…”

A novel signature predicts recurrence risk and therapeutic response in breast cancer patients

“…Supplementing tamoxifen with melatonin has been found to prolong the premetastatic phase in breast cancer patients 11 . Consistent with this, we found that patients with high ASMT expression levels tend to be more sensitive to tamoxifen treatment and experience fewer relapses or longer phases before disease recurrence.…”

Biotransformation of melatonin in human breast cancer cell lines: role of sulfotransferase 1A1

“…As the sensitivity of estrogen‐dependent human breast cancer cell lines to tam was increased at physiological, nocturnal circulating melatonin levels (1 n m ) [43, 44], these interactions might not be relevant in patients. This is in line with data from a phase II study, in which melatonin was able to restore the sensitivity to tam in therapy‐resistant breast cancer patients [45].…”

A Novel Melatonergic Signature Predicts Reccurence Risk and Therapeutic Response in Breast Cancer Patients

“…In a clinical trial, supplementing tamoxifen with melatonin has been found to prolong the pre-metastatic phase in patients with breast cancer [11]. In line with that finding, we found that patients with high ASMT expression levels tend to be more sensitive to treatment with tamoxifen and experience fewer relapses or longer phases before recurrence.…”

A novel signature predicts recurrence risk and therapeutic response in breast cancer patients

“…Supplementing tamoxifen with melatonin has been found to prolong the premetastatic phase in breast cancer patients 11 . Consistent with this, we found that patients with high ASMT expression levels tend to be more sensitive to tamoxifen treatment and experience fewer relapses or longer phases before disease recurrence.…”

Biotransformation of melatonin in human breast cancer cell lines: role of sulfotransferase 1A1

“…As the sensitivity of estrogen‐dependent human breast cancer cell lines to tam was increased at physiological, nocturnal circulating melatonin levels (1 n m ) [43, 44], these interactions might not be relevant in patients. This is in line with data from a phase II study, in which melatonin was able to restore the sensitivity to tam in therapy‐resistant breast cancer patients [45].…”

A Novel Melatonergic Signature Predicts Reccurence Risk and Therapeutic Response in Breast Cancer Patients

“…In a clinical trial, supplementing tamoxifen with melatonin has been found to prolong the pre-metastatic phase in patients with breast cancer [11]. In line with that finding, we found that patients with high ASMT expression levels tend to be more sensitive to treatment with tamoxifen and experience fewer relapses or longer phases before recurrence.…”

A novel signature predicts recurrence risk and therapeutic response in breast cancer patients

“…Supplementing tamoxifen with melatonin has been found to prolong the premetastatic phase in breast cancer patients 11 . Consistent with this, we found that patients with high ASMT expression levels tend to be more sensitive to tamoxifen treatment and experience fewer relapses or longer phases before disease recurrence.…”